15353-j-veluchamy

88 | Chapter 3 References 1. Trottier H, Franco EL: The epidemiology of genital human papillomavirus infection. Vaccine 24 Suppl 1:S1-15, 2006. 2. Woodman CB, Collins SI, Young LS: The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7:11-22, 2007. 3. Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ: Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer 14:395-405, 2014. 4. Zagouri F, Sergentanis TN, Chrysikos D, Filipits M, Bartsch R: Molecularly targeted therapies in cervical cancer. A systematic review. Gynecol Oncol 126:291-303, 2012. 5. Diaz-Padilla I, Monk BJ, Mackay HJ, Oaknin A: Treatment of metastatic cervical cancer: future directions involving targeted agents. Crit Rev Oncol Hematol 85:303-314, 2013. 6. Li Q, Tang Y, Cheng X, Ji J, Zhang J, Zhou X: EGFR protein expression and gene amplification in squamous intraepithelial lesions and squamous cell carcinomas of the cervix. Int J Clin Exp Pathol 7:733-741, 2014. 7. Kersemaekers AM, Fleuren GJ, Kenter GG, Van den Broek LJ, Uljee SM, Hermans J et al. : Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 5:577-586, 1999. 8. Schrevel M, Gorter A, Kolkman-Uljee SM, Trimbos JB, Fleuren GJ, Jordanova ES: Molecular mechanisms of epidermal growth factor receptor overexpression in patients with cervical cancer. Mod Pathol 24:720-728, 2011. 9. Hertlein L, LenhardM, Kirschenhofer A, Kahlert S, Mayr D, Burges A et al. : Cetuximabmonotherapy in advanced cervical cancer: a retrospective study with five patients. Arch Gynecol Obstet 283:109- 113, 2011. 10. Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT et al. : Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol 121:303-308, 2011. 11. Menderes G, Black J, Schwab CL, Santin AD: Immunotherapy and targeted therapy for cervical cancer: an update. Expert Rev Anticancer Ther 16:83-98, 2016. 12. Connor ME, Stern PL: Loss of MHC class-I expression in cervical carcinomas. Int J Cancer 46:1029- 1034, 1990. 13. Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG et al. : Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res 14:2028-2035, 2008. 14. Ferns DM, Heeren AM, Samuels S, Bleeker MCG, de Gruijl TD, Kenter GG, Jordanova ES: Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases. J Immunother Cancer. 2016 Nov 15;4:78.